325.64
price up icon0.11%   0.36
after-market 시간 외 거래: 325.64
loading
전일 마감가:
$325.28
열려 있는:
$327.53
하루 거래량:
595.92K
Relative Volume:
0.65
시가총액:
$42.46B
수익:
$2.35B
순이익/손실:
$-269.70M
주가수익비율:
-155.81
EPS:
-2.09
순현금흐름:
$-75.39M
1주 성능:
+0.88%
1개월 성능:
+4.00%
6개월 성능:
+18.18%
1년 성능:
+38.99%
1일 변동 폭
Value
$322.30
$329.33
1주일 범위
Value
$317.88
$329.87
52주 변동 폭
Value
$205.87
$333.70

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name
명칭
Alnylam Pharmaceuticals Inc
Name
전화
(617) 551-8200
Name
주소
675 WEST KENDALL STREET, CAMBRIDGE, MA
Name
직원
2,230
Name
트위터
@alnylam
Name
다음 수익 날짜
2024-10-31
Name
최신 SEC 제출 서류
Name
ALNY's Discussions on Twitter

ALNY을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 29.19B 3.81B -644.79M -669.77M -6.24

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-07-21 개시 Truist Buy
2025-03-31 개시 Redburn Atlantic Buy
2025-03-24 업그레이드 JP Morgan Neutral → Overweight
2024-11-12 다운그레이드 Wolfe Research Peer Perform → Underperform
2024-10-16 개시 Scotiabank Sector Outperform
2024-08-16 업그레이드 Goldman Neutral → Buy
2024-02-16 다운그레이드 Goldman Buy → Neutral
2024-02-15 개시 Wolfe Research Peer Perform
2023-12-08 개시 Wells Fargo Equal Weight
2023-10-11 다운그레이드 Oppenheimer Outperform → Perform
2023-09-29 개시 Raymond James Outperform
2023-05-05 업그레이드 BMO Capital Markets Market Perform → Outperform
2023-04-26 개시 SMBC Nikko Neutral
2023-03-21 개시 Bernstein Outperform
2023-01-18 개시 Canaccord Genuity Buy
2022-09-09 재개 Morgan Stanley Equal-Weight
2022-07-13 개시 Cantor Fitzgerald Neutral
2022-06-27 다운그레이드 Guggenheim Buy → Neutral
2022-06-07 개시 William Blair Outperform
2022-04-25 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2022-03-01 개시 Citigroup Buy
2022-02-03 업그레이드 Guggenheim Neutral → Buy
2022-01-03 업그레이드 Piper Sandler Neutral → Overweight
2021-11-22 업그레이드 Goldman Neutral → Buy
2021-11-22 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2021-11-01 업그레이드 Oppenheimer Perform → Outperform
2021-10-04 업그레이드 UBS Neutral → Buy
2021-08-04 다운그레이드 Piper Sandler Overweight → Neutral
2021-02-22 다운그레이드 Guggenheim Buy → Neutral
2021-02-12 다운그레이드 Citigroup Buy → Neutral
2021-02-12 재확인 H.C. Wainwright Buy
2021-01-25 다운그레이드 BMO Capital Markets Outperform → Market Perform
2020-09-30 재개 Berenberg Hold
2020-09-08 개시 Citigroup Buy
2020-08-11 다운그레이드 Oppenheimer Outperform → Perform
2020-05-13 개시 RBC Capital Mkts Sector Perform
2020-05-07 다운그레이드 JP Morgan Overweight → Neutral
2020-04-24 재개 Evercore ISI Outperform
2020-03-19 개시 Berenberg Buy
2019-12-19 재확인 Chardan Capital Markets Buy
2019-11-20 개시 Oppenheimer Outperform
2019-11-13 개시 BofA/Merrill Buy
2019-05-23 재개 Goldman Neutral
2019-04-12 개시 Evercore ISI Outperform
2019-03-06 업그레이드 Evercore ISI In-line → Outperform
2019-03-05 업그레이드 Morgan Stanley Equal-Weight → Overweight
2019-01-23 개시 UBS Neutral
2018-10-01 개시 Cantor Fitzgerald Overweight
2018-08-13 재확인 Stifel Buy
2018-08-07 업그레이드 Stifel Hold → Buy
2018-05-04 재확인 Stifel Hold
2018-03-28 개시 Evercore ISI In-line
모두보기

Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스

pulisher
02:10 AM

What drives Alnylam Pharmaceuticals Inc. stock priceMarket-crushing stock picks - Autocar Professional

02:10 AM
pulisher
10:37 AM

Huntington's Disease Clinical, Companies, Therapeutic - openPR.com

10:37 AM
pulisher
05:15 AM

What analysts say about Alnylam Pharmaceuticals Inc. stockTriple-digit growth rates - Autocar Professional

05:15 AM
pulisher
Jul 22, 2025

Alnylam Pharmaceuticals Inc. Stock Analysis and ForecastPowerful profit generation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Alnylam Pharmaceuticals Surges to Top 277 Most Actively Traded Stocks with $412 Million in Trading Volume Following FDA Approval of Patisiran - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

Is Alnylam Pharmaceuticals Inc. a good long term investmentHigh-profit capital plays - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Market Sentiment Around Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - 富途牛牛

Jul 22, 2025
pulisher
Jul 22, 2025

Alnylam (ALNY) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Jul 22, 2025
pulisher
Jul 21, 2025

10 Most Undervalued Healthcare Stocks To Buy According To Analysts - Insider Monkey

Jul 21, 2025
pulisher
Jul 21, 2025

Lexicography: Clear And Unequivocal - The National Law Review

Jul 21, 2025
pulisher
Jul 21, 2025

Lobbying Update: $390,000 of ALNYLAM PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

Truist Securities initiates Alnylam Pharmaceuticals stock with Buy rating By Investing.com - ca.investing.com

Jul 21, 2025
pulisher
Jul 21, 2025

This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Benzinga

Jul 21, 2025
pulisher
Jul 21, 2025

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Jul 21, 2025
pulisher
Jul 19, 2025

Alnylam’s ELEVATE Study: A Closer Look at AHP Treatment and Market Impact - The Globe and Mail

Jul 19, 2025
pulisher
Jul 18, 2025

Alnylam’s ALN-4324: A Promising Step in Obesity Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 17, 2025

Alnylam’s HELIOS-A Study: A Promising Update for hATTR Amyloidosis Treatment - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Alnylam Pharmaceuticals stock price target raised to $290 by Cantor Fitzgerald - Investing.com Canada

Jul 17, 2025
pulisher
Jul 17, 2025

Health Check: How Prudently Does Alnylam Pharmaceuticals (NASDAQ:ALNY) Use Debt? - Yahoo Finance

Jul 17, 2025
pulisher
Jul 17, 2025

Alnylam's 2025 Earnings and Strategic Momentum: A Case for Biotech Leadership and Long-Term Value Creation - AInvest

Jul 17, 2025
pulisher
Jul 17, 2025

Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results - Business Wire

Jul 17, 2025
pulisher
Jul 16, 2025

Alnylam’s ConTTRibute Study: A Closer Look at ATTR Amyloidosis Treatment - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

A Glimpse Into The Expert Outlook On Alnylam Pharmaceuticals Through 10 Analysts - Benzinga

Jul 16, 2025
pulisher
Jul 16, 2025

Amvuttra gains UK approval for heart form of ATTR amyloidosis - The Pharma Letter

Jul 16, 2025
pulisher
Jul 16, 2025

JPMorgan raises Alnylam Pharmaceuticals stock price target on Amvuttra forecast - Investing.com Canada

Jul 16, 2025
pulisher
Jul 15, 2025

Hemophilia Clinical Trials, Companies, Therapeutic - openPR.com

Jul 15, 2025
pulisher
Jul 15, 2025

Alnylam Pharmaceuticals Trading Volume Surges to $289 Million Ranking 356th in Daily Volume - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Alnylam Pharma (ALNY) Receives a Buy from Citi - The Globe and Mail

Jul 15, 2025
pulisher
Jul 14, 2025

Alnylam Pharmaceuticals Trading Volume Drops 41.67% to $199 Million Ranking 472nd - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Jefferies reiterates Buy rating on Alnylam Pharmaceuticals stock, citing strong Amvuttra sales - Investing.com Canada

Jul 14, 2025
pulisher
Jul 14, 2025

What makes Alnylam Pharmaceuticals Inc. stock price move sharplyFree Top Growth Stock Recommendations - beatles.ru

Jul 14, 2025
pulisher
Jul 11, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire

Jul 11, 2025
pulisher
Jul 11, 2025

Gene Therapy Market to Hit US$36.55 Billion by 2032 with 19.4% CAGR | MarketsandMarkets™ - Barchart.com

Jul 11, 2025
pulisher
Jul 11, 2025

Alnylam Pharmaceuticals (ALNY) Target Price Raised by Citigroup | ALNY Stock News - GuruFocus

Jul 11, 2025
pulisher
Jul 11, 2025

Alnylam (ALNY) Receives Price Target Boost from Citi | ALNY Stoc - GuruFocus

Jul 11, 2025
pulisher
Jul 07, 2025

Analyst Maintains Buy Rating and Raises PT for ALNY | ALNY Stock News - GuruFocus

Jul 07, 2025
pulisher
Jul 06, 2025

Alnylam Pharmaceuticals’ SWOT analysis: broad label approval boosts stock outlook - Investing.com

Jul 06, 2025
pulisher
Jul 04, 2025

BMO Capital Maintains ‘Outperform’ Rating on Alnylam Pharmaceuticals, Inc. (ALNY); Raises PT - MSN

Jul 04, 2025
pulisher
Jul 02, 2025

Alnylam Beats Acuitas Claim on Patents in Pfizer Shot Suit (1) - Bloomberg Law News

Jul 02, 2025
pulisher
Jul 01, 2025

Alnylam's Norton site is 'springboard' for expanding manufacturing capacity - The Business Journals

Jul 01, 2025

Alnylam Pharmaceuticals Inc (ALNY) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Alnylam Pharmaceuticals Inc 주식 (ALNY) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Greenstreet Yvonne
Chief Executive Officer
Jun 02 '25
Option Exercise
118.73
19,297
2,291,057
68,245
Greenstreet Yvonne
Chief Executive Officer
May 30 '25
Sale
304.39
31,640
9,630,902
48,948
Greenstreet Yvonne
Chief Executive Officer
Jun 02 '25
Sale
306.00
19,297
5,904,882
48,948
$575.42
price up icon 0.73%
biotechnology ONC
$294.83
price down icon 0.26%
$114.60
price up icon 2.84%
$572.39
price up icon 2.04%
$28.01
price up icon 5.54%
자본화:     |  볼륨(24시간):